BI 765063* is a first-in-class myeloid checkpoint inhibitor.1 By blocking the interaction between myeloid cell-surface molecule signal-regulatory protein alpha (SIRPα) and cluster of differentiation 47 (CD47), SIRPα inhibits suppression of the innate immune system and restores the immune functions of myeloid cells in the tumor microenvironment.1,2
Clinical trials (monotherapy and combination therapy): BI 765063 is currently undergoing investigation as a monotherapy and in combination with ezabenlimab* (BI 754091), a programmed cell death protein-1 (PD-1) inhibitor, in a Phase I trial involving patients with solid tumors.3,4
Myeloid cells are an important immune cell type in many solid tumors and their presence in a tumor is often associated with poor prognosis.4 Members of the SIRP family are mainly expressed on the surface of myeloid cells and contribute to the complex interaction between membrane proteins and leukocytes that regulate the body’s innate immune response.2,5
SIRPα is an inhibitory member of the SIRP family that binds to the receptor CD47. CD47 is highly expressed in many different types of cancer and transduces inhibitory signals through SIRPα on macrophages and other myeloid cells.2,6 The SIRPα/CD47 axis is a critical regulator of myeloid cell activation and serves as a myeloid-specific immune checkpoint.6
Mechanism of action
The interaction of SIRPα with CD47 contributes to immune suppression in the tumor microenvironment by inhibiting phagocytosis of tumor cells, downregulation of antigen-presenting cells and maintenance of myeloid-derived suppressor cells.1,5 BI 765063 blocks the interaction of SIRPα with CD47, thereby restoring the immune functions of myeloid cells in the tumor microenvironment.1
Preclinical studies in murine tumor models have demonstrated the clinical benefit of SIRPα antagonist monotherapy, but suggest that clinical outcomes may be enhanced through combination therapy with an adaptive PD-1 immune checkpoint inhibitor, or with a co-stimulatory agent (such as anti-4-1BB monoclonal antibody), to provide dual activation of innate and acquired immunity.5,6
BI 765063 is currently undergoing investigation as a monotherapy and in combination with ezabenlimab (BI 754091) in a Phase I trial involving patients with solid tumors.3,4
|Trial number||Phase||Treatment||Patient population||Status|
BI 765063 (monotherapy and in combination with ezabenlimab [BI 754091])
Patients with advanced solid tumors that have a SIRPα polymorphism, including at least one V1 allele
Boehringer Ingelheim. Data on file.
Barclay AN, et al. Nat Rev Immunol 2006;6(6):457–64
Boehringer Ingelheim and OSE Immunotherapeutics. Press release. https://ose-immuno.com/wp-content/uploads/2019/06/EN_190617_BI-765063_FirstPatientDosed.pdf (Accessed: February 2021).
ClinicalTrials.gov. NCT03990233. https://clinicaltrials.gov/ct2/show/NCT03990233 (Accessed: February 2021).
Gauttier V, et al. Cancer Res 2018;78(13 Suppl.): Abstract 1684.
Weiskopf K. Eur J Cancer 2017;76:100–9.
Cotechini T, et al. Cancer J. 2015;21:343–50.
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
© 2021 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: March 2021
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue